INTRODUCTION
Breast lymphoma is rare clinical entity. The disease may arise in both sexes, while it occurs almost exclusively in women. About 25-40% of non-Hodgkin's lymphoma (NHL) patients present with a primary extranodal origin [1, 2] , and the extranodal lymphoma could arise in almost every organ in the body [2, 3] . However, because of paucity of the lymphoid tissue in the breast [4] , primary breast lymphoma (PBL) and secondary involvement of the breast thesurgery.or.kr by lymphoma are rare [5, 6] .
PBL is diagnosed when the breast is the first site or major manifestation of the lymphoma, and there is no documentation of lymphoma elsewhere, except the ipsilateral axillary node [7] . PBL accounts for more than 40% of cases of breast lymphoma [8] . PBL has been rarely reported, and accounts for less than 1% of all NHL and 1.7-2.2% of extranodal NHL [1, 9] . Diffuse large B-cell lymphoma (DLBL) is the most common histologic type of PBL, whereas low grade lymphomas, including mucosal-associated lymphoid tissue (MALT) lymphoma, marginal zone B-cell lymphoma and follicular lymphoma (FL), are the majority of disseminated lymphomas involving the breast [8] .
Surgery, chemotherapy and/or radiotherapy, as either monotherapy or combined treatment have been reported as treatment modalities for PBL.
Due to the rarity of PBL, limited information about this disease in Korean women is available. Here, we report our experience of the clinicopathologic characteristics and treatment outcomes of this rare disease in our institution.
METHODS
We retrospectively reviewed the electronic database of the Samsung Medical Center, Seoul, Korea, for the years between 1997 and 2009. Twenty three patients with infiltration of lymphoid malignant cells in the mammary tissue were identified. We adapted the original criteria of PBL by Wiseman and Liao [7] , PBL was diagnosed when the patients fulfilled the following criteria: 1) technically adequate pathologic specimen, 2) close association of breast tissue and lymphomatous infiltration, 3) absence of previous extramammary lymphoma and 4) no evidence of widespread documentation of a similar histologic type of the lymphoma except in the ipsilateral axillary lymph nodes. Among the 23 patients, 9 women met the eligibility criteria for PBL, and a retrospective review was conducted.
All patients were diagnosed histologically by excisional biopsy or core needle biopsy. All pathologic specimens were reviewed by a pathologist, and the histologic type of lymphoma was classified according to the World Health Organization classification [10] based on morphologic examination of hematoxylin & eosin stain coupled with immunohistochemical stains. Patients were staged according to the Ann Arbor system [11] , and the prognostic index was evaluated for all patients according to the International Prognostic Index (IPI) score [12] . Initial staging procedures included a complete blood count, chemistry, chest X-ray, mammography, breast sonography and computed tomography of the thorax, abdomen and pelvis. Aspirate and bone marrow biopsy was performed in all cases. Treatment response was assessed after initial treatment, and response criteria was determined following the guidelines published by the National Cancer Institute [13] .
Complete remission (CR) was defined as the complete disappearance or no evidence of all detectable clinical and radiological evidence of disease and disease-related symptoms after systemic therapy or local therapy. Partial remission (PR) was defined as at least 50% decrease in the sum of the products of the greatest diameters (SPD). Stable disease (SD) was defined as less than a PR but is not progressive disease. Relapsed or progressive disease was considered when new lesions appeared or at least 50% increase from nadir in the SPD of any previously involved lesions after CR, or after PR or SD. Relapse-free survival (RFS) was defined as the time from diagnosis until disease relapse after CR or last follow-up, and disease-specific survival (DSS) was defined as the time from diagnosis until death as a result of the disease or last follow-up.
We used the Kaplan-Meier method to estimate the RFS and DFS. Statistical analyses were performed using PASW ver. 18.0 (IBM Co., Armonk, NY, USA).
RESULTS

Clinicopathologic characteristics
A total of 9 patients were identified. Table 1 lists the baseline characteristics of patients. All patients were female. All specimen was diagnosed with DLBL ( Fig. 1 ).
All The median age at diagnosis was 47.9 years (range, 28 was measured in all patients, and no patient had an elevated serum LDH.
Treatment and clinical outcomes
The median follow-up time was 44 months (range, 18 to 90 months). First-line therapy and clinical outcomes are documented in Table 2 thesurgery.or.kr Study Group [14] and a prospective study of 96 patients [15] . However, most reports regarding Korean PBL patients are retrospective and included small numbers of patients [16] [17] [18] [19] . For these lesions, we report our experience of PBL in a single institution. To the best of our knowledge, this is one of the largest series in Korea women.
According to the definition set out by Wiseman and
Liao [7] , PBL is diagnosed when the breast is the first or and Bcl-6, and negatively for the CD3, CD5 and CD10.
The prognosis of PBL has been reported that the behavior and clinical outcomes are similar to that of systemic lymphomas of the same histological types and stages.
Therefore, prognostic factors for patient with PBL have been reported as histologic subtype, IPI, the use of anthracycline containing chemotherapy and/or radiation therapy [14, 20] , stage according to the Ann Arbor staging system [20] , LDH level and age [9, 26] . In a report by Ryan et al. [14] of 204 patients with primary DLBL of the breast, the median overall survival period was 8.0 years, and the median progression free period was 5.5 years. Our result showed similar results that estimated DSS and RFS were 6.4 years and 5.4 years, respectively. These results are improved over those of previous reports of Korean women with PBL. In a reports by Park et al. [18] , the median overall survival and disease-free survival were calculated as 12 months and 6.5 months, respectively. We do not fully explain the exact cause of the differences in prognosis between our results and those of Park et al. [18] , but the different prognosis may arise from differences in patients' characteristics and from improvements in treatment modalities.
There have been controversies regarding the treatment of PBL. In general, PBL treatment is similar to that of patients with systemic lymphoma of similar histologic type.
Combination chemotherapy with or without radiation therapy is accepted as the main treatment method. A prospective study by Aviles et al. [15] , found that the 10 year rate of event-free survival was 50%, 57%, and 83% for radiotherapy, chemotherapy, and combined therapy, respectively. Rituximab, a monoclonal antibody targeting the CD20 antigen, is known to have high efficacy for DLBL, and R-CHOP has been the mainstay for treatment of B-cell lymphoma [27] . However, due to the low in- Surgery is only recommended for diagnostic purposes, and is not recommended as a first line therapy, as extensive surgery may delay the beginning of chemotherapy [14] . Furthermore, Misra et al. [28] and Park et al. [18] suggested that surgery should be performed only after the local failure of systemic treatment. In our study, one patients received operation not for diagnostic purpose and the patient underwent a lumpectomy with sentinel lymph node biopsy because of an unsatisfactory diagnosis before the operation. Due to the small numbers in our series, no conclusions can be drawn regarding the prognosis according to stage and treatment methods.
In conclusion, due to the rarity of the PBL, there have thesurgery.or.kr 
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